Oncology and Hematology
Episodes 145-160 of 300
Sara A. Hurvitz, MD, FACP
Tiffany Traina, MD, FASCO
Gregory Vidal, MD, PhD
Stephanie Walker, RN
Charles Turck, PharmD, BCPS, BCCCP
Richard T. Penson, MD, MRCP
Sarah Rutherford, MD
John P. Leonard, MD
Kami Maddocks, MD
Matthew J. Matasar, MD
John P. Leonard, MD
Sarah Rutherford, MD
John P. Leonard, MD
Sarah Rutherford, MD
Alison J. Moskowitz, MD
Alex Herrera, MD
Kami Maddocks, MD
Matthew J. Matasar, MD
John P. Leonard, MD
Matthew J. Matasar, MD
Alex Herrera, MD
Kami Maddocks, MD
Alison J. Moskowitz, MD
Sarah Rutherford, MD
Matthew J. Matasar, MD
Kami Maddocks, MD
Alex Herrera, MD
Alison J. Moskowitz, MD
Alex Herrera, MD
Alison J. Moskowitz, MD
Paul P. Doghramji, MD, FAAFP
Rami Komrokji, MD
Allan Platt, PA-C, MMSc
- CME/CE Broadcast Replay
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
1.00 creditNeeraj Agarwal, MD, FASCO
- Project Oncology®
Poster Pearl: Detecting Cancer with an MCED Test and Treating It Surgically Improves Outcomes
Charles Turck, PharmD, BCPS, BCCCP
Adam H. Buchanan, MS, MPH
